News GeNeuro SA

Equities

GNRO

CH0308403085

Market Closed - Euronext Paris Other stock markets 11:28:26 2024-04-24 am EDT			5-day change	1st Jan Change
1.43 ^EUR	0.00%		-0.69%	+31.19%

Mar. 20	Geneuro SA Announces Appointments of Board of Directors	CI
Feb. 02	GeNeuro: share price falls after private placement	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting	Mar. 20	BU
Geneuro SA Announces Appointments of Board of Directors	Mar. 20	CI
GeNeuro: share price falls after private placement	Feb. 02	CF
GeNeuro Raises EUR5 Million from Share Issue	Feb. 02	MT
GeNeuro appoints new Chief Medical Officer	Jan. 08	CF
Geneuro Sa Announces Executive Changes	Jan. 05	CI
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold	Jan. 05	CF
GeNeuro - Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications	Dec. 12	AQ
GeNeuro: positive opinion for continuation of trial	Dec. 11	CF
GeNeuro's Mid-stage Study for Post-COVID Symptoms Therapy Gets Medical Committee's Nod	Dec. 11	MT
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications	Dec. 11	CI
GeNeuro Finalizes Patient Enrollment in Early-stage Trial of Long-COVID Treatment	Nov. 28	MT
GeNeuro: end of recruitment for Covid long trial	Nov. 28	CF
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024	Nov. 28	CI
GeNeuro : Investor Presentation October 2023	23-10-20	PU
GeNeuro and Verily Collaborate to Advance Long-COVID Research	23-10-19	CI
GeNeuro : Half yearly financial reports and audit reports/limited reviews / Half yearly financial report	23-10-06	PU
GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update	23-10-03	AQ
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
GeNeuro - New study published in PNAS further substantiates the neuropathogenic role of the HERV-W protein in MS	23-09-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GeNeuro SA

Equities

GNRO

CH0308403085

Summary

Filters